How many insider trades does FilingIQ track for SLN?

FilingIQ tracks 17 Form 4 insider transactions for SLN (Silence Therapeutics plc), covering filings from Aug 3, 2025 onwards. 6 of those were filed in the last 90 days.

Are SLN insiders net buyers or net sellers?

Across the full Form 4 history for SLN, 2 transactions (12%) were open-market purchases and 8 (47%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SLN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SLN in?

Silence Therapeutics plc (SLN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $210.19M.

SLN insider trading

Healthcare

Silence Therapeutics plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

12% / 47%

Market cap

$210.19M

About Silence Therapeutics plc

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Company website: www.silence-therapeutics.com

SLN insider activity at a glance

FilingIQ has scored 17 insider transactions for SLN since Aug 3, 2025. The most recent filing in our index is dated Jul 6, 2026.

Across the full history, 2 open-market purchases and 8 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live SLN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,099

UNITED THERAPEUTICS Corp

APLS 274

Apellis Pharmaceuticals, Inc.

KYMR 232

Kymera Therapeutics, Inc.

GH 194

Guardant Health, Inc.

13F funds holding SLN

Lombard Odier Asset Management (USA) Corp

$82.96M · 3.2% of AUM

Artal Group S.A.

$60.04M · 1.5% of AUM

Frequently asked

How many insider trades does FilingIQ track for SLN?: FilingIQ tracks 17 Form 4 insider transactions for SLN (Silence Therapeutics plc), covering filings from Aug 3, 2025 onwards. 6 of those were filed in the last 90 days.
Are SLN insiders net buyers or net sellers?: Across the full Form 4 history for SLN, 2 transactions (12%) were open-market purchases and 8 (47%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SLN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SLN in?: Silence Therapeutics plc (SLN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $210.19M.

Methodology & sources

Every SLN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.